REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has received an average rating of “Moderate Buy” from the eight research firms that are presently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts […]
REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Rating of "Moderate Buy" from Brokerages theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) and Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership. Valuation and Earnings This table compares VYNE Therapeutics […]
Kenneth Mills, President and CEO of Regenxbio Inc (NASDAQ:RGNX), executed a sale of 45,000 shares in the company on December 19, 2023, according to a recent SEC Filing.
REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) CEO Kenneth T. Mills sold 45,000 shares of the business’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $19.68, for a total transaction of $885,600.00. Following the transaction, the chief executive officer now owns 355,289 shares in the company, […]